Article ID Journal Published Year Pages File Type
2510225 Antiviral Research 2011 15 Pages PDF
Abstract

Nucleoside and nucleotide analogs have served as the cornerstones of antiviral therapy for many viruses. However, the requirement for intracellular activation and side-effects caused by distribution to off-target sites of toxicity still limit the efficacy of the current generation of drugs. Kinase bypass strategies, where phosphorylated nucleosides are delivered directly into cells, thereby, removing the requirement for enzyme catalyzed phosphorylation steps, have already changed the face of antiviral therapy in the form of the acyclic nucleoside phosphonates, cidofovir, adefovir (given orally as its dipivoxil prodrug) and tenofovir (given orally as its disoproxil prodrug), currently used clinically. These strategies hold further promise to advance the field of antiviral therapy with at least 10 kinase bypass and tissue targeted prodrugs, representing seven distinct prodrug classes, currently in clinical trials. This article reviews the history of kinase bypass strategies applied to nucleoside antivirals and the evolution of different tissue targeted prodrug strategies, highlighting clinically relevant examples.

► Nucleoside and nucleotides are the cornerstones of antiviral therapy. ► Requirement for activation and side-effects limit the efficacy of the current drugs. ► Kinase bypass strategies could further advance the field of antiviral therapy. ► At least 10 prodrugs, from seven different classes, are in clinical trials.

Related Topics
Life Sciences Immunology and Microbiology Virology
Authors
, ,